A model for predicting the risk of cancer consequent to retroviral gene therapy

Human Gene Therapy

Volumn 3, Issue 5, 1992, Pages 479-486

  Moolten, Frederick L ^a,b   Cupples, L Adrienne ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANIMAL; ARTICLE; DNA VECTOR; GENE THERAPY; GENETICS; HUMAN; MUTATION; NEOPLASM; RETROVIRUS; RISK; STATISTICAL MODEL;

ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMAN; MODELS, STATISTICAL; MUTATION; NEOPLASMS; RETROVIRIDAE; RISK; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0026941999     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1992.3.5-479     Document Type: Article

References (27)

1. BARBACID, M. (1987). Ras genes. Annu. Rev. Biochem. 56, 779-827.
2. BOOKSTEIN, R., and LEE, W-H. (1991). Molecular genetics of the retinoblastoma suppressor gene. Crit. Rev. Oncogenesis 2, 211-227.
3. BUCHBERG, A.M., BEDIGIAN, H.G., JENKINS, N.A., and COPELAND, N.G. (1990). Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol. Cell. Biol. 10, 4658-4666.
4. CORNETTA, K., MOEN, R.C., CULVER, K., MORGAN, R.A., McLACHLIN, J.R., STURM, S., SELEGUE, J., LONDON, W., BLAESE, R.M., and ANDERSON, W.F. (1990). Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1, 15-30.
5. CORNETTA, K., MORGAN, R.A., and ANDERSON, W.F. (1991a). Safety issues related to retroviral-mediated gene transfer in humans. Hum. Gene Ther. 2, 5-14.
6. CORNETTA, K., MORGAN, R.A., GILLIO, A., STURM, S., BALTRUCKI, L., O'REILLY, R., and ANDERSON, W.F. (1991b). No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene Ther. 2, 215-220.
7. CUYPERS, H.T., SELTEN, G., QUINT, W., ZIJLSTRA, M., MAANDAG, E.R., BOELENS, W., VAN WEZENBEEK, P., MELIEF, C., and BERNS, A. (1984). Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37, 141-150.
8. FEARON, E.R., and VOGELSTEIN, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
9. FRANKEL, W., POTTER, T.A., ROSENBERG, N., LENZ, J., and RAJAN, T.V. (1985). Retroviral insertional mutagenesis of a target allele in a heterozygous murine cell line. Proc. Natl. Acad. Sci. USA 82, 6600-6604.
10. HENDERSON, E.S. (1983). Acute leukemia. In Hematology, 3rd ed. W.J. Williams, E. Beutler, A.J. Erslev, and M.A. Lichtman, eds. (McGraw-Hill, New York, NY) pp. 221-223.
11. KELSEY, C.A. (1987). X-ray properties. In Essentials of radiologic imaging, 5th ed., J.H. Juhl and A.B. Crummy, eds. (J.B. Lipincott, Philadelphia), p. 17.
12. LEDLEY, F.D. (with 12 co-investigators). (1991). Clinical protocol. Hepatocellular transplantation in acute hepatic failure and targeting genetic markers to hepatic cells. Hum. Gene Ther. 2, 331-358.
13. LEHMANN, A.R., and STEVENS, S. (1977). The production and repair of double strand breaks in cells from normal humans and from patients with ataxia telangiectasia. Biochim. Biophys. Acta 474, 49-60.
14. LOEB, L.A. (1991). Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079.
15. LUPTON, S.D., BRUNTON, L.L., KALBERG, V.A., and OVERELL, R.W. (1991). Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell Biol. 11, 3374-3378.
16. MOOLTEN, F.L. (1990). Mosaicism induced by gene insertion as a means of improving chemotherapeutic selectivity. Crit. Rev. Immunol. 10, 203-233.
17. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
18. MOOLTEN, F.L., WELLS, J.M., HEYMAN, R.A., and EVANS, R.M. (1990). Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1, 125-134.
19. POTTEN, C.S., and LAJTHA, L.G. (1982). Stem cells versus stem lines. Ann. NY Acad. Sci. 397, 49-61.
20. ROHDEWOLD, H., WEIHER, H., REIK, W., JAENISCH, R., and BREINDL, M. (1987). Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J. Virol. 61, 336-343.
21. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., STRATFORDPERRICAUDET, L., PERRICAUDET, M., GUGGINO, W.B., PAVIRANI, A., LECOCQ, J., and CRYSTAL, R.G. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
22. SEIDMAN. H., MUSHINSKI, M.H., GELB, S.K., and SILVERBERG, E. (1985). Probabilities of eventually developing or dying of cancer - United States, 1985. Ca 35, 36-56.
23. STRAUSS, B.S. (1992). The origin of point mutations in human tumor cells. Cancer Res. 52, 249-253.
24. TEMIN, H.M. (1990). Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1, 111-123.
25. VARMUS, H.E. (1984). The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 18, 553-612.
26. VARMUS, H.E., QUINTRELL, N., and ORTIZ, S. (1981). Retroviruses as mutagens: Insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell 25, 23-36.
27. WILSON, J.M., GROSSMAN, M., CABRERA, J.A., WU, C.H., and WU, G.Y. (1992). A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes. J. Biol. Chem. 267, 11483-11489.